Vical expands infectious disease portfolio with novel antifungal from Astellas
Vical announced it has expanded its infectious disease portfolio with the addition of a novel antifungal, ASP2397, in-licensed from Astellas Pharma. ASP2397 represents a potential new class of antifungal compounds to address invasive Aspergillus infections, including transplant recipients. April 01, 2015